Imitab®
Imatinib Mesylate BP Film Coated Tablet
Brand Name:
Imitab®100
Generic Name:
Imatinib Mesylate
Strength:
100mg
Description:
Beige colored, round shaped film coated tablet
Pack Size:
3 X 10 Tablets
Brand Name:
Imitab®400
Generic Name:
Imatinib Mesylate
Strength:
400mg
Description:
Light orange colored, capsule shaped film coated tablet
Pack Size:
3 X 10 Tablets
* Storage Conditions: Store below 30 °C temperature. Keep away from light and wet place. Keep out of reach of children.
Approved Indications of Imitab
- Philadelphia chromosome positive chronic myeloid leukemia (CML).
- Philadelphia chromosome positive acute lymphoblastic leukemia (ALL).
- Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Follow-up is limited to 5 years
- Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.
- Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. There are no controlled trials in pediatric patients demonstrating a clinical bene t, such as improvement in disease-related symptoms or increased survival.
- Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
- Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.
- Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.
- Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR fusion kinase negative or unknown.
- Adult patients with unresectable, recurrent and/or metastatic dermato brosarcoma protuberans (DFSP).
- Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).